{"name":"Biosplice Therapeutics, Inc.","slug":"biosplice-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"Biosplice Therapeutics, Inc. is a private biopharmaceutical company based in San Diego, California. It was founded in 2008 by Osman Kibar.","hq":"","founded":2008,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMizwJBVV95cUxPNVRSMUtERVNLT3BpVk9iVkJnS1ZNdFc5QmZIOXVtcTdFcFVtaWtqRnB5WVNpRGp1WE8yNkYwYUMyZFlnaXAyaG5abXlPZS0tZXdIWlZvTmZ0ci1od0VHZkM1cE41bXRmaWFjVzFwcTVZbFdISWMwZ0gxc0hYZW9KZnJBLV9aYXQzdXV3S2E2c0pmOElDRnNzRlJiOHlxMURoYUdjR0tnNUFzNUdZSTNOUGpDRFJwU0lFY2RHTnpuQWlfUDhiVm04RXVDVlFFUV9IczM2cEtlWDJWbVZTQlR2dDkzOURkZ29IWUZuUFJHbll2TXhuYU42ZFRpSVloVG9QVE0tSl93Z21sdVNRLXNTcURZdUNmUGc2czRIcTZETTUxbllPTTNjV1FuNG5MWWQzVTA3V3Q2SVFLZTE5TGRFeFpwQ0l1eTlQbUxsbl9uYw?oc=5","date":"2026-03-25","type":"trial","source":"Barchart.com","summary":"Osteoarthritis Clinical Trial Pipeline Advances as 100+ Companies Develop 110+ Novel Therapies Across All Clinical Stages, Finds DelveInsight | Biosplice Therapeutics, Regeneron Pharmaceuticals - Barc","headline":"Osteoarthritis Clinical Trial Pipeline Advances as 100+ Companies Develop 110+ Novel Therapies Across All Clinical Stage","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE5FYXhORGh2cVlRVHI0TG84ZVZMOGVaQ2VLX3BaYXlwSUFQZmpaU1ZzaWw4U1h2MkM5dlRhQVBkNngtTjdwYkxlSzVoRW9sMlJiWVZ1d0VYVU5VY1hTMlpZdkFuMGo0QVF3N0tPa0hB0gFyQVVfeXFMTlI2Y2c1aUFoVXVtaEUxZU1oSENQZDgxVlZpOUVXVGRrdGhXSDBtcDh5LUVvcDJtNHZTSGFvS3dEeHpzRUQ3T2hEYnZDb2gzQVRjejJiWXU1Z0k1TkhDYlhLbHAydmVweGhQUGU2bm5jT3B3?oc=5","date":"2026-01-07","type":"regulatory","source":"koreabiomed.com","summary":"Samil Pharm-linked osteoarthritis drug advances toward US FDA approval - koreabiomed.com","headline":"Samil Pharm-linked osteoarthritis drug advances toward US FDA approval","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxQT01ZQkk5ODRicHBmRGJlaE95S01kY1lpam44azY4SWtHeDlKS3BWaFRYMDR0QnBKUnBmTWlhZ2Q4M0NhUDBiQ3RXNGwtTFRJOEZvRWdpaFNQb3JYVzMxNGpfQWpKTlRGaDZSZnY4a0hMbU9pXzFydGE0YnhkaHZkUdIBlAFBVV95cUxQS3VCeV93TGNvU0xZQ29lVWNockNVM3o1dGc1TnVQOWJRNURFYUZZVzlSWDlpMXFoMk1wLW5UZFBSenpPWGxsWXdlSVRuSWduZjVDSTg0VzFzUWRXdlI1S2I0TnhBSmpsWXRKWkhsRDRwY3ZOeXNad2ZOOElvN0x0SzlBVTN0MjdLZ2VmZ0lBRG1qMjZB?oc=5","date":"2026-01-07","type":"regulatory","source":"Chosunbiz","summary":"Samil Pharmaceutical seeks FDA approval for Lorecivivint to slow knee osteoarthritis progression - CHOSUNBIZ - Chosunbiz","headline":"Samil Pharmaceutical seeks FDA approval for Lorecivivint to slow knee osteoarthritis progression - CHOSUNBIZ","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMipgJBVV95cUxPX0wtaFBqTTdDbUY0QmdkeWZPSUlEUWh2NzBsSVlTY3lyNXpoTmVrUkRVV29kcjVxUktzWkVWcndmRnRNbWk5TnB6NkVFMk9raTI4ZnFLNVdoaEF6WHR6STJCTWJ2WGdUWExjclN4NE43bXZPQmJyankybW1NQWNJaXBLSUFLVXdlNy1JU1dSMmctUDZ3ZXgxNFN2UlVUSnJSalY4aXRjSkdBbkJUVi1EZHBZV3QwTi1IOVJXQlphY0dwaEZ0MUNvUXMxODdBXzU2TkVQRm1URTlXMDhoaVE4b2VhTTk2S3I4WHdtekZzcGJkUkVCWWFhVS03LVZPQWd0SWJFTVJXWVdQMDBZWDdzNUl0QjNIbTBzdkptLXFycS1Hay1CaWc?oc=5","date":"2026-01-06","type":"pipeline","source":"GlobeNewswire","summary":"Biosplice Announces the Submission of its New Drug - GlobeNewswire","headline":"Biosplice Announces the Submission of its New Drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9wFBVV95cUxQNk10S2RsVS1CRG1WeVBjVTN3N0pIbUE5TnRrdjh0TWJkZmluZ1FlS2tDdnl5clNYV1VMcXFFYjhKTlRNUVJadEJWeFRsd01hUnRXeVlLLXpmYWtwMWg2Y2lkX0g5b09RX3JEcjB5a1k1TXlUbHNqZ0t3bFl6TGE1Vy1fVXZYcWlsQmJkMmVDR3F3NWVTYjFqbnUwdGREQkF4TUk3aFBRMVQ3Q3ZaQ1MxWXYtRk9feGpHVlFwUEJRbF9URDlaTmVOOTlnU2k2N3VUQzg2MlJteGtlMHZxMlY0QmVFbXhFdVZlUmdRYi1TbFZNcDAtREVz?oc=5","date":"2024-10-24","type":"pipeline","source":"GlobeNewswire","summary":"Global Anti-Aging Products Market is Projected to Cross ~USD 112 Billion by 2030 | DelveInsight - GlobeNewswire","headline":"Global Anti-Aging Products Market is Projected to Cross ~USD 112 Billion by 2030 | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAJBVV95cUxPejRGZWJpTmZNNWVJdm9YTHBrVk5xakRVV1NsbVhjQUxiVm9rbTc5OXBkMUpfVmRGMW9MOFpCcUliakR0emU4UjBrWUNIZWZQRlhoVEU1ODhHUWcxOGdkY3hIektmaGRoVDJMX1hTSllXTnBjbi1qYlE3cHY5QTN1SW1VcHpnc1NJbDdpcElkZW5JbmNiZ24taE5sVWRWZ0VIVkNYOHdvSTZXYVpKOXZDSFpNLVFlOEZJaFFxQkFLckM4WlA1aTJwT01XcW4xREsya0JYT1JJcHRHYmJwMExJNzRmeEYzZU1kTVNNdm5kVUlzN2xvcEJpWG8wNnBoU000N2Z4N2FvSU5pY29zeVFHNkVMbUU3RzhSbFh0a0hQNVE0eVFOQk4wdjBZYlg?oc=5","date":"2024-08-15","type":"pipeline","source":"GlobeNewswire","summary":"Global Non-Steroidal Anti-Inflammatory Drugs Market is - GlobeNewswire","headline":"Global Non-Steroidal Anti-Inflammatory Drugs Market is","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxOMVJ6S2lRdVBrUUdkbThFY3lhQkpyLWRkNThmNUR6OUI5QW1MczhtWHM3dnBEWTZTa2tpS3k4ekhsU0RlaEljMjBZRlBOYkd4QXBIQVZMenZsV2w3bEhoNDU1eVVMVnFaVXZ5aDN3ZEdqNzF5bDBJdkpwSS00LUVEQ0Qtd3RUWURNSlo1WWEzbHdFX09HQ1QwVkJCemdhRkVUd05LVHNyYzlYY1VJMURsYVY4ZjlubzROYkJvYl9JRXI1Wmd5dDVLVA?oc=5","date":"2024-06-13","type":"deal","source":"Contract Pharma","summary":"Biosplice, Novo Nordisk Partner to Develop Drug Candidates for Treatment of Diabetes - Contract Pharma","headline":"Biosplice, Novo Nordisk Partner to Develop Drug Candidates for Treatment of Diabetes","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMieEFVX3lxTE9wdlZ1Mk9vZ04taDlWUW13bGUxQkp2bThZN0dGZFRmYlRXOF93RDB4T1ZtbEQ0QUk1dUNJMWMwcG1WRVBBS3FicjhvOUtha2tSS2RhVmRqZjBJWlZkWDd5LWNWUWpPUzVpLVJ4OWpwaklZZjlGU09PRg?oc=5","date":"2023-08-24","type":"pipeline","source":"drugdiscoverytrends.com","summary":"30 biotech startups leading in pharmaceutical innovation - drugdiscoverytrends.com","headline":"30 biotech startups leading in pharmaceutical innovation","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxOcndfNUNRNU05ck1VaTN1LTBkR1NzYklVNXQ0T3VKQlpIM2JWcWZGYWl1dnB0dEM5RVJsd0E1RlhOZ3BjTWtWLXYzV1dLZmxFX3VVN1hMRlFBYzE2Z0NpQzJobFZPb1Raa1VYcE1WTll2cHRlZWZvVzBISGU0TEdTX0RENGtzOHFGcEdMR2hRemx6NlBUR2pVNm00aVNKb0VMcmdEWlctMGJzcFJCNGlqYkhSRTNJMmFM?oc=5","date":"2022-02-08","type":"pipeline","source":"Fierce Biotech","summary":"After reaching a high with $12B valuation, Biosplice lays off staff and axes baldness program - Fierce Biotech","headline":"After reaching a high with $12B valuation, Biosplice lays off staff and axes baldness program","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigJBVV95cUxNNjUzRWdWcVVoM3J2OWY1eFJpTXNMbVNPR2VQVWVwTkFDZTE2Q0FYRElNQ0JiYlJ6b3NScFlnbW43YzJ4OTdyUGFDMWUxQ1RTWEgtemR4cmpKX1FKcHNtNUh0Qk04T3V5bWZYeERaVXI1WmdydW1Sak5HVlVCNGxub2huY0p4bzRhVk9JYkJ4ekRsdlVHMkY5ZDFLVzJaMDZhWHF4SkpUTElZclRjZlY4UG81RGNvSDB0QTBSbFlHbzc4NjBnZWdPcXZYellOaEhGcDlVZVRtOF9LbXF6amk0bWkybC1pSVZ6Y3hlQnF6dXdndEw3ZVd2TkdsdlRlSkZkV0g1U2NkaktFQQ?oc=5","date":"2021-04-15","type":"pipeline","source":"GlobeNewswire","summary":"Biosplice Therapeutics Closes $120 Million in Equity Financing to Advance Its Alternative Splicing Platform - GlobeNewswire","headline":"Biosplice Therapeutics Closes $120 Million in Equity Financing to Advance Its Alternative Splicing Platform","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE02ZGtSZ0JpaGhfNHlLUGotdk5rSENkd1pYQnNvdElXR0hCbUhGUXlUeFJ1WTNtcTZ2b2g5dG9wSTBqOXlsYmpSMEo2SzNwcmtjZWREblo2Y2t1aTFILV92WEMxMHMtMHVuT2xUYUN30gFyQVVfeXFMTUR6OXB0el9BQjU3UVpnNUdRNlhrZDQwTWR1OEFKLUdrcm5STXZMMjdfXzE2SklLMlJVbXl4MU1lS2RqU3hkdDJ5aVpoOFUzUnp1QVNNWlI1N3dMQlNjTDhfUVMtZUVYWnR0WGJCN1BuSE13?oc=5","date":"2021-03-30","type":"pipeline","source":"koreabiomed.com","summary":"Samil to develop, sell US osteoarthritis treatment in Korea - koreabiomed.com","headline":"Samil to develop, sell US osteoarthritis treatment in Korea","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":5,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}